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Abstract
Background: The Korean Society of Hypertension has published the Korea Hypertension Fact Sheet 2020 to
provide an overview of the magnitude and management status of hypertension and their recent trends.
Methods: The Fact Sheets were based on the analyses of Korean adults aged 20 years or older of the 2007–2018
Korea National Health and Nutrition Examination Survey (KNHANES) and the 2002–2018 National Health Insurance
Big Data (NHI-BD).
Results: Currently, the population average of systolic/diastolic blood pressure was 118/76 mmHg in Korean adults
aged 20 years or older showing little change in the recent decade. However, the number of people with
hypertension increased steadily, exceeding 12.0 million. Indeed, the number of people diagnosed with
hypertension increased from 3.0 million in 2002 to 9.7 million in 2018. During the same period, the number of
people using antihypertensive medication increased from 2.5 million to 9.0 million, and the number of people
adherent to treatment increased from 0.6 million to 6.5 million. Hypertension awareness, treatment, and control
rates increased rapidly until 2007, but showed plateaued thereafter. In 2018, the awareness, treatment, and control
rates of hypertension among all adults were 67, 63, and 47%, respectively. However, the awareness and treatment
rates were only 17 and 14% among adults aged 20 to 39 years old with hypertension. Among patients treated for
hypertension, 61% of them were also using glucose-lowering or lipid-lowering drugs. Among antihypertensive
prescriptions, 41% of the patients received monotherapy, 43% received dual therapy, and 16% received triple or
more therapy. The most commonly prescribed antihypertensive medication was angiotensin receptor blockers,
followed by calcium channel blockers and diuretics.
Conclusion: To achieve further improvement in management of hypertension, we need to encourage awareness
and treatment in young adults. It is required to develop tailored prevention and management strategies that are
appropriate for and inclusive of various demographics.
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Introduction
High blood pressure is the most important modifiable
risk factor yet also the biggest contributor to cardiovas-
cular and cerebrovascular diseases [1, 2]. In the twenty-
first century, cardiovascular and cerebrovascular diseases
mortality accounts for nearly a half of all deaths in the
developed regions and for one quarter in the developing
regions [3]. The cardiovascular disease mortality rate has
been decreasing in Korea; nonetheless, heart disease,
cerebrovascular disease, and high blood pressure remain
the second, fourth, and tenth in the causes of death [4].
Moreover, due to the rapid aging of the population and
improved prognosis from cardiovascular event, the abso-
lute number of patients with cardiovascular disease
continues to increase. According to the National Health
Insurance Service (NHIS) statistics in Korea, the
estimated medical cost of treating hypertension was
3830 billion Korean Won, accounting for 4% of all
medical expenses or 16% of medical expenses for
chronic diseases [5]. Hitherto, controlling blood pressure
is crucial not only to reduce the burden of disease at a
societal level but also to improve the quality of life at an
individual level. Continuous monitoring of hypertension
prevalence and management status should be the first
step in reducing its burden. To achieve this, the Korean
Society of Hypertension had published its first Hyperten-
sion Fact Sheet in 2018 [6] and have been periodically
updating it thereafter.
Materials and methods
The Korea Hypertension Fact Sheet 2020 analyzed
two nationally representative datasets. The first one is
the Korea National Health and Nutrition Examination
Survey (KNHANES) from 1998 to 2018. The KNHA
NES is a national surveillance system in Korea that
assesses the health and nutritional status of noninsti-
tutionalized Korean population since 1998 [7]. The
second one is the National Health Insurance (NHI)
Big Data from 2002 to 2018. Organized by the
National Health Insurance Service (NHIS), the NHI
Big Data contains socio-demographics, hospital claims
with International Classification of Diseases, 10th
Revision (ICD-10) coding, and mortality data of the
entire population of Republic of Korea [8]. Previously,
the Korea Hypertension Fact Sheet 2018 analyzed
adults aged 30 years from the KNHANES data and
people of all age in the NHI Big Data. This year, the
Korea Hypertension Fact Sheet 2020 included adults
aged 20 years or older from both datasets.
The English version of the “Korea Hypertension Fact
Sheet 2020” is attached as a supplementary material of
this manuscript, and the Korean version is also available
at http://www.koreanhypertension.org/reference/guide.
Analysis of the KNHANES from 1998 to 2018
There have been 7 rounds of KNHANES between 1998
and 2018. The first three KNHANES were conducted
every 3 years: KNHANES I (1998), KNHANES II (2001),
and KNHANES III (2005). Since 2007, each survey has
consisted of 3 years: KNHANES-IV (2007–2009), KNHA
NES VII (2010–2012), and KNHANES VII (2016–2018).
A total of 153,797 adults (average 21,971 per each
survey) was analyzed. Hypertension was defined as sys-
tolic blood pressure (SBP) ≥140 mmHg, diastolic blood
pressure (DBP) ≥90mmHg, or self-reported use of anti-
hypertensive medication for the purpose of blood pres-
sure control. Awareness rate was defined as the
proportion of people with physician diagnosis of hyper-
tension among all people with hypertension. Treatment
rate was defined as the proportion of people using
antihypertensive drugs for 20 days or more per month
among all people with hypertension. Control rate was
defined as the proportion of people with SBP < 140mmHg
and DBP < 90mmHg among 1) all people with hyperten-
sion and 2) people treated for hypertension [7, 9]. To
evaluate the magnitude and management status of hyper-
tension without the effects of population aging, age-
standardized rates were calculated based on the demo-
graphics of the Korean population in 2005 according to
the Population and Housing Census, Statistics Korea.
Analysis of the NHI big data from 2002 to 2018
A repeated cross-sectional analysis of 114 million cases
of hypertension (assuming 1 case per calendar year if
observed more than once) was conducted. While the
KNHANES data analysis defined hypertension based on
measured blood pressure levels and use of antihyperten-
sive medication, the NHI big data analysis defined
hypertension based on diagnosis codes, because the
claim database did not have records of blood pressure
measurements. Healthcare utilization was defined as at
least one health insurance claim for diagnosis of essen-
tial hypertension (ICD-10: I10) each year. Treatment of
hypertension was defined as at least one health insur-
ance claim for hypertension diagnosis with antihyperten-
sive drug prescription each year. Adherence to
treatment was defined as receiving prescriptions of anti-
hypertensive drugs ≥290 days (80%) each year. Antihy-
pertensive drugs were classified into diuretics (DU;
thiazide-related diuretics, loop diuretics), beta-blockers
(BB), calcium channel blockers (CCB), angiotensin con-
verting enzyme inhibitors (ACEi), angiotensin receptor
blockers (ARB), potassium-sparing diuretics (PSD), or
others (alpha-blockers, vasodilators, etc.). If the regimen
of antihypertensive drug had switched in a year, one
with the longest duration was selected as the representa-
tive prescription of the patient for the given year. Com-
plication screening rates were calculated for blood test
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(≥1 serum creatinine test) and ≥ 1 routine urinalysis and/
or urine microalbumin test each year, separately. The
estimated hypertension burden and management status
were additionally calculated for young adults aged 20–
39 years.
Results
Magnitude of hypertension: based on the KNHNAES
The average blood pressure of Korean adults has
decreased between 1998 and 2008, but there has been
no significant change in the last 10 years. Population
mean SBP/DBP level was 118/76 mmHg for Korean
adults aged 20 years or older and 119/77mmHg for
adults aged 30 years or older (Supplement, page 9). Over
the last 20 years, the age-standardized mean blood pres-
sure levels have decreased yet without significant change
in recent years. The age-standardized prevalence of
hypertension also modestly decreased from 26.0% (men
29.6%, women 22.3%) in 1998 to 23.5% (men 28.0%,
women 18.6%) in 2018 (Supplement, page 10). However,
with the rapid aging of the population, the absolute
number of people with hypertension has steadily
increased; as of 2018, the number has exceeded 12 mil-
lion. The prevalence of hypertension increased with age
in both sex (Supplement, page 11). The sex-specific
prevalence was higher in men until the sixth decade and,
thereafter, higher in women.
Hypertension management status: based on the KNHA
NES
In general, the hypertension management (awareness,
treatment, and control rates) has improved significantly
over the past two decades. In 2018, among adults aged
20 or older with hypertension, the awareness rate was
67%, the treatment rate was 63%, and the control rate
was 47% (Supplement, page 5). However, the degree of
management varied greatly by age. All management indi-
ces have improved significantly in older adults but not
in younger adults. Among patients under age 50 with
hypertension, awareness, treatment, and control rates
remained below 50%. (Supplement, pages 13–15).
Healthcare utilization for hypertension: based on the NHI-
big data
The number of people diagnosed with hypertension has
increased 3.2 times from 3 million in 2002 to 9.7 million
in 2018. People receiving antihypertensive prescription
has also increased 3.6 times from 2.5 million in 2002 to
9.0 million in 2018. More importantly, the number of
people adherent to antihypertensive medication has
increased more than tenfold from 0.6 million in 2002 to
6.5 million in 2018 (Supplement, page 18). The use of
combination therapy has rapidly increased, with 40.7%
using one class, 43.2% using two classes, and 16.1% using
three or more classes of antihypertensive drug in 2018
(Supplement, page 20). In 2018, the most commonly
prescribed antihypertensive drug class was ARB (71.4%),
followed by CCB (60.4%), DU (25.8%), BB (16.0%), ACEi
(2.0%), and PSD (1.8%), respectively (Supplement, page
21). ARB (47.3%) and CCB (39.9%) were commonly used
for monotherapy, while ACEi/ARB plus CCB was the
most frequently prescribed dual therapy regimen
(Supplement, page 22).
Hypertension in young adults: based on the KNHAES and
NHI-big data
When extrapolating the KNHANES 2018 data to the
entire Korean population, it is estimated that 1.27
million young adults (20–39 years) have hypertension.
This accounts for nearly 10% of all adults with hyperten-
sion. However, the analysis of NHI-Big Data suggested
that, among the 2451 thousand adults with undiagnosed
hypertension, 959 thousand (39%) of them were between
the age 20 to 39 years (Supplement, page 25). According
the KNHANES data from 1998 to 2018, the awareness
and treatment rates of hypertension have been steadily
rising in older adults but improved little in younger
adults. Indeed, the awareness and treatment rates among
adults age 20–39 years with hypertension were 17.4 and
13.7%, respectively (Supplement, page 26–27).
Discussion
The Korea Hypertension Fact Sheet 2020 provides an
overview on the magnitude and management status of
hypertension in Korea. Although the population average
blood pressure and the prevalence of hypertension have
changed little over the last decade, the absolute number
of people with hypertension have increased steadily-now
exceeding 12 million due to population aging. Hyperten-
sion management status in Korea had greatly improved
until 2007 but remained stagnant thereafter. The great-
est novelty of the Korea Hypertension Fact Sheet lies on
its generalizability; the KNHANES provides unbiased
sampling of the Korean population, and the NHI-Big
Data provides medical service uses of the entire nation.
However, there are some limitations to be addressed.
First, the KNHANES is based on non-institutionalized
residents of Korea; thus, it might not include people
with severe diseases. Second, the exact collection
methods and survey details varied across the KNHA
NES. Despite standardized protocols and rigorous qual-
ity control procedures, such variability may have affected
the analysis on secular trends. Third, the NHI-Big Data
may not be optimal for identifying disease occurrence
and prevalence, because the data have been collected for
medical service claims and reimbursement purposes.
Fourth, the adherence to antihypertensive medication
was evaluated on a prescription basis. Thus, it is possible
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that adherence was overestimated, because we cannot
ascertain whether the drug was actually taken or not.
Fifth, we were limited to anonymized datasets; therefore,
the data linkage between the two datasets was
unachievable.
Conclusions
Despite the significant improvement in hypertension
management over the past few decades, there is still
room for further improvement. In particular, the hyper-
tension management status was concerning in younger
age groups, regardless of sex. To achieve further im-
provements in management, it is essential to enable
early seeking for disease status and to encourage treat-
ment in young adults. To prevent complications and
death from hypertension, emphasizing the importance of
treatment adherence and blood pressure control remains
a top priority. We also need to develop tailored preven-
tion and management strategies that are appropriate for
and inclusive of various demographics.
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